The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Rapid Response Innovation Awards, 2009The Role of Casein Kinase 2 in the Modulation of Dopamine Signaling in Parkinson's Disease
Objective/Rationale:
Parkinson’s disease is caused by a selective loss of cells in the brain that produce the neurotransmitter dopamine. The major treatment for PD is Levodopa (L-Dopa) which gets... -
Target Validation, 2009The Transcription Factor Nrf2 as a Target to Reduce Neurodegeneration and Neuroinflammation in Parkinson's Disease
Objective/Rationale:
Dopaminergic neuron loss and exacerbated neuroinflammation are events tightly involved in PD pathology that may result from an inadequate response to toxic, oxidant or inflammatory... -
Target Validation, 2009Neuroprotection by PXDNL, a Novel Heme-containing Peroxidase
Objective/Rationale:
Dysfunction of mitochondria in nerve cells contributes to the neurodegeneration of PD. When cells are infected by the CMV virus, they become resistant to certain mitochondrial... -
Target Validation, 2009Validation of Nox1/Rac1, a Novel Molecular Source of Reactive Oxygen Species in the Nigrostriatal Pathway, as a Target for Parkinson's Disease Therapy
Objective/Rationale:
A family of NADPH oxidase (NOX) is the specialized enzyme complex which generates superoxide. We demonstrate that Nox1, a NOX homologue, is upregulated in DA cells under various... -
Target Validation, 2009Pharmacological Regulation of Endogenous GDNF Expression in the Adult Brain
Objective/Rationale:
GDNF is a potent trophic factor for dopamine neurons in the adult brain. Exogenous GDNF supplementation strategies, however, are fraught with technical difficulties associated with... -
Target Validation, 2009The Polo Like Kinases (PLK2 and PLK3) as Therapeutic Targets for Parkinson's Disease
Objective/Rationale:
Phosphorylation of alpha-synuclein at serine 129 is characteristic of Parkinson's disease (PD) and related alpha-synulceinopathies. Unraveling the role of phosphorylation in...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.